Baig Biotech (688276): Continued release of the shingles vaccine focuses on the pace of sales throughout the year
Huayuan Securities released a research report on April 25 stating that it gave Baike Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) the burden of shingles disease is high, with more than 1.5 million new cases per year;
Baig Bio (688276): A healthy dose of chickenpox and shingles can be expected
Southwest Securities released a research report on April 23 stating that it gave Baig Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) continuous dosage of the shingles vaccine; 2) quarterly fluctuations in shingles vacci
Baike Biotech (688276): Shingles drives performance growth, influenza vaccine dosage upgrade is imminent
Baig Biotech (688276): Shingles vaccine release drives performance growth
Baike Biotech (688276): Shingles vaccine strongly drives growth, innovative vaccines open up future space
Baike Biotech (688276): Blisters boost performance and expect continued growth
Baike Biotech (688276): The contribution of shingles to elasticity continues to advance in the research pipeline
Baig Biotech (688276): Performance is in line with expectations, rapid release of domestically produced shingles vaccine
Baig Biotech (688276): Performance is in line with expectations, focus on shingles vaccine dosage
Baig Biotech (688276): Performance is in line with expectations, focus on shingles vaccine dosage
Baike Biotech (688276): Shingles is increasing in volume driven by volume
Baig Biotech (688276): Rapid dose development of the shingles vaccine continues to advance
Baig Biotech (688276): Accelerated release of shingles, influenza impairment affects profits
Baike Biotech (688276): The performance is in line with expectations and is expected to continue to be released as a substitute
Baike Biotech (688276): The performance is in line with the expected continuous dose of shingles
Research Report Nuggets丨CICC: Baike Biotech's annual net profit slightly exceeded expectations, maintaining the “outperforming industry” rating
Baig Biotech (688276): The 2023 revenue forecast is in line with the expected rapid release of the shingles vaccine
Baike Biotech (688276) Company Review: Shingles Vaccine Drives Growth Performance Forecast Exceeds Expectations
No Data